title: Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.
abstract: Cognitive impairment is known to be a core deficit in schizophrenia. Existing treatments for schizophrenia have limited efficacy against cognitive impairment. The ubiquitous use of nicotine in this population is thought to reflect an attempt by patients to selfmedicate certain symptoms associated with the illness. Concurrently there is evidence that nicotinic receptors that have lower affinity for nicotine are more important in cognition. Therefore, a number of medications that target nicotinic acetylcholine receptors (nAChRs) have been tested or are in development. In this article we summarize the clinical evidence of nAChRs dysfunction in schizophrenia and review clinical studies testing either nicotine or nicotinic medications for the treatment of cognitive impairment in schizophrenia. Some evidence suggests beneficial effects of nAChRs based treatments for the attentional deficits associated with schizophrenia. Standardized cognitive test batteries have failed to capture consistent improvements from drugs acting at nAChRs. However, more proximal measures of brain function, such as ERPs relevant to information processing impairments in schizophrenia, have shown some benefit. Further work is necessary to conclude that nAChRs based treatments are of clinical utility in the treatment of cognitive deficits of schizophrenia.
authors.forename: Douglas L
authors.initials: DL
authors.lastname: Boggs
authors.forename: Jon
authors.initials: J
authors.lastname: Carlson
authors.forename: Jose
authors.initials: J
authors.lastname: Cortes-Briones
authors.forename: John H
authors.initials: JH
authors.lastname: Krystal
authors.affiliation: Yale University School of Medicine, VACHS 151, 950 Campbell Avenue, West Haven CT 06516- 2770. Douglas.boggs@yale.edu.
authors.forename: D Cyril
authors.initials: DC
authors.lastname: D'Souza
mesh_terms: D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000378:metabolism / Q000502:physiology; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012565:Schizophrenic Psychology; D012651:Self Medication; D012907:Smoking
chemical_list: D018722:Nicotinic Agonists; D018697:Nootropic Agents; D011978:Receptors, Nicotinic; D009538:Nicotine